Printer-friendly versionPrinter-friendly version

Prevention of viral hepatitis in Germany and the Nordic Countries: lessons learnt and the way forward

Berlin, Germany, October 13-14, 2003

- Meeting Programme -

Monday, October 13, 2003

Session 1 Opening and objectives

Chair: Lars Rombo, Sweden, and Johannes Hallauer, Germany

09.00 - 09.30

  • Welcome
    Johannes Hallauer, Germany

  • Introduction of the participants

  • Objectives of the meeting:

    1. Update of the epidemiological situation on viral hepatitis in Germany and the Nordic Countries;

    2. Overview of surveillance systems for infectious diseases and adverse events following vaccination in Germany and the Nordic Countries;

    3. Evaluation of current prevention and control measures on viral hepatitis in Germany and Nordic Countries;

    4. Lessons learnt from the experiences in German and the Nordic Countries; successes, problems and barriers to overcome, and the way forward.

  • Review of the meeting programme

  • Epidemiology, prevention, and control of viral hepatitis in Germany and the Nordic Countries - Pre-meeting document 360 Kb (.pdf)

 

Session 2 Epidemiology, prevention, and surveillance of viral hepatitis in the Nordic Countries

Chair: Lars Rombo, Sweden, and Johannes Hallauer, Germany

 09.30 - 10.10
Hepatitis B epidemiology, surveillance, and prevention strategies in the Nordic Countries 146 Kb (.pdf)
Hans Blystad, Oslo, Norway

10.10 - 10.25
Epidemiology of hepatitis A in Sweden - the same old story?  298 Kb(.pdf)
Lars Rombo, Eskilstuna, Sweden

10.25 - 10.45
Coffee break

10.45 - 11.05
Problems associated with the introduction of HBsAg-positive children in day care centres 72 Kb (.pdf)
Johan Struwe, Huddinge, Sweden

11.05 - 11.25
Investigation of a cluster of nosocomial HBV infections in Sweden - obstacles and efforts 331 Kb (.pdf)
Johan Struwe, Huddinge, Sweden

11.25 - 11.55
Hepatitis A and B outbreaks among intravenous drug users in the Nordic Countries 134 Kb (.pdf)
Hans Blystad, Oslo, Norway

11.55 - 12.25
Evaluation of a hepatitis B selective vaccination programme in Norway  78 Kb (.pdf)
Hanne Nøkleby, Oslo, Norway

12.25 - 14.00
Lunch

Session 3 Epidemiology of viral hepatitis in Germany

Chair: Peter Grob, Switzerland, Daniel Shouval, Israel

 14.00 - 14.25
Hepatitis C infection in medical settings
Sergei Viazov, Essen, Germany

14.25 - 14.50
Follow-up of iatrogenous HCV infections related to anti-Rh prophylaxis
Anne-Sophie Endres, Berlin, Germany

14.50 - 15.15
Epidemiology of hepatitis A in Germany 262 Kb (.pdf)
Katharina Alpers, Berlin, Germany

15.15 - 15.30
Coffee break

15.30 - 15.55
Epidemiology of hepatitis B in Germany 244 Kb (.pdf)
Doris Radun, Berlin, Germany

15.55 - 16.20
Molecular epidemiology of HBV mutants 2,234 Kb (.pdf)
Wolfram Gerlich, Giessen, Germany

Session 4 The health care system in Germany

Chair: André Meheus, Belgium

16.20 - 16.45
Organisation of the health care system in Germany 416 Kb (.pdf)
Johannes Hallauer, Berlin, Germany

 

 Session 5 Surveillance systems in Germany  

Chair: André Meheus, Belgium

 16.45 - 17.10
Federal law on communicable diseases (Infektionsschutzgesetz) - Reporting systems 258 Kb (.pdf)
Michael Kramer, Bonn, Germany

 

Tuesday, October 14, 2003

 Session 6  Prevention and control of viral hepatitis in Germany

Chair: Nicole Guérin, France, and Andrei Lobanov, Denmark

09.00 - 09.30
Development of hepatitis B prevention in Germany - the first 10 years 82 Kb (.pdf)
Wolfgang Jilg, Regensburg, Germany

09.30 - 10.00
Screening pregnant women for hepatitis B: results from two studies 88 Kb (.pdf)
Wolfgang Jilg, Regensburg, Germany

10.00 - 10.35
Groups at risk for hepatitis B infection - who should be vaccinated  121 Kb (.pdf)
Ulrich Bienzle, Berlin, Germany

10.35 - 11.00
Coffee break

Session 7 Evaluation of viral hepatitis prevention and control measures in Germany 

Chair: Harold Margolis, USA, and Daniel Lavanchy, Switzerland

11.00 - 11.25
Universal vaccination against hepatitis B in Germany – a paediatrician’s point of view 101 Kb (.pdf)
Uwe Büsching, Bielefeld, Germany

11.25 - 11.50
Monitoring system for adverse events following hepatitis vaccination
Johannes Hallauer, Berlin, Germany, and round-table discussion

11.50 - 12.15
School-entry monitoring of vaccination status 399 KB (.pdf)
Günter Pfaff, Stuttgart, Germany

12.15 - 12.40
Critical review of programme progress 62 Kb (.pdf)
Michael Kramer, Bonn, and Johannes Hallauer, Berlin, Germany

12.40 - 14.00
Lunch

Session 8 Conclusions of the meeting 

Chair: Mark Kane, USA, and Wolfgang Jilg, Germany

14.00 - 15.30
Presentation of the VHPB meeting conclusions, including discussion 97 Kb (.pdf)
David FitzSimons, Geneva, Switzerland

15.30
Close of the meeting

Tags: